September 9, 2017
Nearly 200 academic and industry researchers came together to share updates on innovative preclinical and clinical-stage Alzheimer’s disease research at the 18th Annual Conference on Alzheimer's Drug Discovery.
April 4, 2017
Our new investment in M3 Biotechnology is advancing its drug program toward clinical trials
March 3, 2017
We recently awarded eight new grants totaling over $4 million to advance treatments for Alzheimer’s and related dementias. Several of the awards support new approaches to treating these diseases.
February 2, 2017
Dr. Michela Gallagher of Agenebio is developing AGB101, which can potentially prevent mild cognitive impairment from progressing to Alzheimer's disease.
January 1, 2017
We awarded three new grants in November and December, totaling nearly $2.5 million. The grants represent our commitment to advancing the most promising drugs to clinical trials, the final stages of drug development.
December 12, 2016
We have supported over 20% of all Alzheimer's treatments currently in clinical trials. One of the most promising is C-31, developed by Frank Longo, MD, PhD.
November 11, 2016
The Alzheimer’s Drug Discovery Foundation awarded three new grants in September and October totaling nearly $1.5 million.
September 9, 2016
The ADDF awarded three new grants in July and August for potential new treatments for Alzheimer's and other dementias.
July 7, 2016
The ADDF awarded five new grants in May and June 2016, totaling nearly $1.5 million.
May 5, 2016
The ADDF has awarded 10 new grants to researchers developing drugs for neurodegenerative diseases and biomarkers to detect their onset and progression.